Zydelig

Idelalisib

• Brand(s): Zydelig
• Dosage Form/Strength: 100 mg, 150 mg Tablets

For the treatment of patients with relapsed chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) in combination with Rituximab.

Exclusion criteria:
Patients whose disease has progressed on ibrutinib therapy in the relapsed setting are not eligible to receive idelalisib.

Note: Patients who have experienced intolerance but not disease progression to ibrutinib in the relapsed setting may switch to idelalisib. Documentation on the nature of the intolerance is required.

Renewals will be considered for patient who has not experienced disease progression while on idelalisb (Zydelig) therapy.

Funded Dose:
Idelalisib will be funded in combination with up to 8 cycles of rituximab at the recommended dose of 150 mg orally twice daily and will continue following the completion of the rituximab portion of the regimen.

EAP Drug Request Form:

Standard Form for EAP Drug Requests